Labrador Iron Mines Holdings Limited (LBRMF)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	-0.58	-0.67	-0.64	-0.31	13.01	0.17
Depreciation & Amortization	0.04	0.04	0.05	0	-25.96	0.02
Loss (Gain) From Sale of Assets	-	-	-	-	-	-0.7
Asset Writedown & Restructuring Costs	-	-	-	-	-	-0.05
Stock-Based Compensation	0.1	0.1	0.1	0.33	0.68	-
Provision & Write-off of Bad Debts	-	-	-	-	-	0.04
Other Operating Activities	-0.02	0.01	-0.12	-0.82	12.35	-0.66
Change in Other Net Operating Assets	0.39	0.53	0.33	-0.26	-0.52	0.32
Operating Cash Flow	-0.07	0	-0.28	-1.06	-0.43	-0.87
Capital Expenditures	-0.09	-0.09	-0.07	-0.1	-0.44	-
Sale of Property, Plant & Equipment	-	-	-	-	0.2	1.05
Sale (Purchase) of Intangibles	-	-	-	0.25	0.5	-
Other Investing Activities	-	-	-	0.89	0.2	-
Investing Cash Flow	-0.09	-0.09	-0.07	1.04	0.47	1.05
Short-Term Debt Issued	-	0.13	0.1	-	-	0.4
Long-Term Debt Issued	-	-	-	-	0.04	-
Total Debt Issued	0.23	0.13	0.1	-	0.04	0.4
Short-Term Debt Repaid	-	-	-	-	-	-0.4
Long-Term Debt Repaid	-	-0.05	-0.05	-	-	-
Total Debt Repaid	-0.05	-0.05	-0.05	-	-	-0.4
Net Debt Issued (Repaid)	0.19	0.08	0.05	-	0.04	-
Financing Cash Flow	0.19	0.08	0.05	-	0.04	-
Net Cash Flow	0.02	-0	-0.3	-0.02	0.07	0.18
Free Cash Flow	-0.16	-0.08	-0.35	-1.16	-0.87	-0.87
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.01	-0.01	-0.01
Levered Free Cash Flow	0.11	0.21	-0.03	0.52	-9.2	-0.34
Unlevered Free Cash Flow	0.11	0.21	-0.03	0.52	-9.2	-0.34
Change in Net Working Capital	-0.44	-0.57	-0.37	-0.15	-0.07	-0.43

Source: S&P Global Market Intelligence. Standard template. Financial Sources.